Investing.com - Biofrontera ADR reported on Wednesday third quarter earnings that matched analysts' forecasts and revenue that was inline with expectations.
Biofrontera ADR announced earnings per share of €-0.2 on revenue of €7.95M. Analysts polled by Investing.com anticipated EPS of €-0.2 on revenue of €7.95M.
Biofrontera ADR shares are down 38.41% from the beginning of the year and are trading at €4.490 , down-from-52-week-high.They are under-performing the Nasdaq which is up 23.54% from the start of the year.
Biofrontera ADR follows other major Healthcare sector earnings this month
Biofrontera ADR's report follows an earnings beat by Pfizer on Tuesday, November 2, 2021, who reported EPS of €1.34 on revenue of €24.09B, compared to forecasts EPS of €1.08 on revenue of €22.58B.
Novo Nordisk ADR had beat expectations on Wednesday, November 3, 2021 with third quarter EPS of €0.8209 on revenue of €5.55B, compared to forecast for EPS of €0.7768 on revenue of €5.39B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar